Skip to Content

Q4 2022 EPS Estimates for Thermo Fisher Scientific Inc. (NYSE:TMO) Analyst slash

Q4 2022 EPS Estimates for Thermo Fisher Scientific Inc. (NYSE:TMO) Analyst slash

Thermo Fisher Scientific, Inc. is the name of that particular business. The analysts working for Thermo Fisher Scientific, SVB Leerink employs, have lowered their profit projections for the fourth quarter of 2022 in a research report made public on Friday, January 6. The earnings per share that the medical research company is expected to declare for the quarter will be $5.16, which is a decrease from the $5.17 that it reported for the previous period, as stated by P. Souda of SVB Leerink. SVB Leerink has given the company an “outperform” rating and determined that a price objective of $620.00 is appropriate. At this time, Thermo Fisher Scientific anticipates generating $23.04 in earnings per share throughout the entirety of this year. Thermo Fisher Scientific is expected to bring in $25.89 in profits per share for the fiscal year that will end in 2024, according to projections made by SVB Leerink.
On October 26, a report detailing the recent financial performance of Thermo Fisher Scientific (NYSE: TMO) was made available to the public. The results of the medical research company’s quarterly earnings per share came in at $5.08, which is $0.30 more than the average projection of $4.78. The results of the company’s earnings came in at $5.08, even though the average projection was $4.78. The company’s high net margin of 15.92% and high return on equity of 22.97% are indicators of Thermo Fisher Scientific’s successful performance. The company’s quarterly sales came in at $10.68 billion, significantly higher than the $9.86 billion industry analysts anticipated they would report. This figure represents a significant increase from the previous quarter’s sales.
At the beginning of the trading week, one share of Thermo Fisher Scientific stock was valued at $535.00. A debt-to-equity ratio comes in at 0.65; a quick ratio comes in at 1.22; a current ratio comes in at 1.74; and a quick ratio comes in at 1.22. The company currently has a simple moving average of $539.47 for the past 50 days and a simple moving average of $544.93 for the past 200 days. There is a possibility that the price of Thermo Fisher Scientific will range anywhere from $475.77 to $631.89 over a single year. The high market value of the company, which is $209.82 billion, its price-to-earnings ratio of 30.07, its price-to-earnings-growth ratio of 1.87, and its beta of 0.83 all point to the fact that the company is in a sound financial position. Additionally, the company has a price-to-earnings-growth ratio of 1.87, which indicates that it is an attractive investment.
Earlier reports cover a wide range of topics, one of which is TMO, the topic of discussion. While maintaining their “outperform” rating on the stock, Robert W. Baird lowered their price target on shares of Thermo Fisher Scientific from $711.00 to $696.00 in a research note published on Thursday, October 27. The information regarding Deutsche Bank Aktiengesellschaft’s intention to cover the shares of Thermo Fisher Scientific was included in a report that was made public on December 13. They suggested making a “buy” investment in the company and established a price target of $620.00. In a report made public on December 6 of this year, the Royal Bank of Canada was the first financial institution to cover shares of Thermo Fisher Scientific. They have given the company an “outperform” rating and have determined that the price target for it should be in the range of $661.00. The share price objective for Thermo Fisher Scientific was lowered by Wells Fargo & Company in a report that was published on January 3. The new target price is $505.00, down from $525.00. The rating on the stock was reassessed and now stands at “neutral,” up from the previous “underweight” rating. Barclays lowered their price objective on shares of Thermo Fisher Scientific from $575.00 to $570.00 while maintaining an “overweight” rating on the stock in a research note published on Tuesday, November 29. One financial advisor has suggested selling the stock, two market analysts have suggested keeping the stock, and nine market analysts have suggested purchasing the stock. According to the information made available by Bloomberg, the stock is given an average recommendation of “Moderate Buy,” It is projected to reach a price of $627.30 per share.
Recent deals involving the company’s shares involved institutional buyers and sellers. DZ Bank AG, also known as Deutsche Zentral Genossenschaften Bank Frankfurt am Main, increased the amount of Thermo Fisher Scientific stock owned by 168.1% over the second quarter. DZ BANK AG, Deutsche Zentrale Genossenschafts Bank Frankfurt am Main, now owns a total of 2,014,472 shares of the medical research company’s stock, which has an estimated market value of $1,094,244,000 following the purchase of an additional 1,262,989 shares throughout the previous period. During the third quarter, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. added more shares of Thermo Fisher Scientific to its holdings at a rate that was 394.8 percent higher than in the previous quarter. Following the acquisition of an additional 886,075 shares during the most recent period, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now possesses 1,110,504 shares of the medical research company’s stock are currently valued at $563,237,000. This brings the total number of shares owned by the company to 1,110,504, which is an increase of 886,075. After making additional purchases of Thermo Fisher Scientific stock during the third quarter, the investment portfolio of the Ontario Teachers Pension Plan Board experienced a value increase of approximately $433,169,00. This was due to the portfolio’s increased size. During the second quarter, Jennison Associates LLC increased its Thermo Fisher Scientific holdings by 416.0%, higher than the previous quarter’s. Jennison Associates LLC successfully acquired an additional 525,014 shares in the medical research company over the month. This brings the total number of shares owned by the company to 651,227, which have a value of $353,799,000. The Canada Pension Plan Investment Board (CPPIB) made a new investment during the third quarter of 2018, bringing the total value of its Thermo Fisher Scientific stock to approximately $209,946,000 at the end of the period. The combined holdings of institutional investors and hedge funds account for 85.92% of the total number of shares in the company.
On November 3, the company’s Chief Executive Officer, Marc N. Casper, sold 8,200 shares of the company’s stock. This is another piece of news about the company. The total value of the sold shares was $3,997,090.00, which works out to a price of $487.45 per share on average when those shares were sold. Following the conclusion of the sale, the chief executive officer is now the direct owner of 178,005 shares of the company’s stock. The total value of these shares is $86,768,537.25, so the CEO’s stake in the company is now worth $86,768,537.25. If you click on this link, you will be taken to a legal filing that was made with the SEC, which will give you more information regarding the transaction and take you there immediately. On Monday, October 31, Chief Executive Officer Marc N. Casper sold 10,000 shares of the company’s stock. This development is just one piece of recent information regarding the company. The total value of the shares sold was $5,099,700.00, which works out to a price of $509.97 for each share on average when they were sold. Following the fruitful conclusion of the transaction, the Chief Executive Officer will now have 178,005 shares of the company, the total value of which is equal to $90,777,209.85. An SEC document that can be accessed through the SEC website provides a comprehensive explanation of the transaction, which can be read there.
On top of that, President and Chief Executive Officer Marc N. Casper sold 8,200 shares of the company’s stock on November 3. The total value of the sold shares was $3,997,090.00, which works out to a price of $487.45 per share on average when those shares were sold. After the completion of the sale, the Chief Executive Officer now owns 178,005 shares of the company, which have an estimated value of $86,768,537.25. The disclosure about the purchase can be found in this particular location. In the past three months, company insiders have generated $16,073,443 in proceeds from selling 31,475 shares of the company’s stock. The company’s insiders own 0.43 percent of the total number of shares outstanding.
Thermo Fisher Scientific stated on November 10 that its Board of Directors had authorized a stock repurchase program with a total value of $4 billion. The statement was part of a larger news release. Because of this buyback authorization, the medical research company now has the authority to repurchase up to 2% of its shares of stock from the open market. This authority was granted as a result of the buyback authorization. When a company plans to buy back its stock, it almost always indicates that management thinks the stock is trading at an attractive price.

Tags

Leave a comment

Your email address will not be published. Required fields are marked *